Immunotherapy boosts chemo before stomach cancer surgery in new trial
NCT ID NCT06576921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding the immunotherapy drug serplulimab to standard chemotherapy before surgery helps patients with advanced stomach or gastroesophageal junction cancer. About 116 participants will receive either the combo or chemo alone for three cycles before and after surgery. The main goal is to see if the combo increases the rate of complete tumor disappearance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
serplulimab (an immunotherapy drug) combined with chemotherapy (nab-paclitaxel, S-1, oxaliplatin)
What this could lead to
If it works, this could lead to a more effective pre-surgery treatment for advanced stomach cancer, helping more patients achieve complete tumor removal.
What could go wrong
This is an early phase 2 trial with only 116 participants, so results may not apply to everyone. Adding immunotherapy to chemo can increase side effects like immune-related inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Digestive surgery, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi' an, China
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of General Surgery, Tangdu Hospital, Air Force Medical University
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of General Surgery, The 986th Military Hospital, Air Force Medical University
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The fourth hospital of Hebei Medical University
RECRUITINGShijiazhuang, Heibei Province, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••